Article info

Original research
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Authors

  • Montserrat Puigdelloses Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Neurology, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marc Garcia-Moure Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Sara Labiano Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Virginia Laspidea Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marisol Gonzalez-Huarriz Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marta Zalacain Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Lucia Marrodan Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Naiara Martinez-Velez Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Daniel De la Nava Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Iker Ausejo Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Sandra Hervás-Stubbs Program in Immunology and Immunotherapy, Foundation for the Applied Medical Research, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Guillermo Herrador Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • ZhiHong Chen Department of Oncological Sciences, The Tisch Cancer Institut and Department of Neurosurgery, Mount Sinai Icahn School of Medicine, New York, New York, USA PubMed articlesGoogle scholar articles
  • Dolores Hambardzumyan Department of Oncological Sciences, The Tisch Cancer Institut and Department of Neurosurgery, Mount Sinai Icahn School of Medicine, New York, New York, USA PubMed articlesGoogle scholar articles
  • Ana Patino Garcia Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Hong Jiang Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Candelaria Gomez-Manzano Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Juan Fueyo Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Jaime Gallego Perez de Larraya Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Neurology, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marta Alonso Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPrograms in Solid Tumors and Neuroscience, Foundation for the Applied Medical Research, Pamplona, SpainDepartment of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Marta Alonso; mmalonso{at}unav.es; Dr Jaime Gallego Perez de Larraya; jgallego{at}unav.es
View Full Text

Citation

Puigdelloses M, Garcia-Moure M, Labiano S, et al
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Publication history

  • Accepted June 16, 2021
  • First published July 19, 2021.
Online issue publication 
July 19, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.